Roche sells three drugs to Actavis

Roche has agreed to sell three of its products to the Iceland-based generics company Actavis Group. The deal covers the cardiovascular drugs Bezalip and Rapilysin and dermatology med Neotigason, with combined 2006 sales of $117.3 million. Roche will continue to sell the remedies in Latin America under license from Actavis. The deal is part of Roche's strategy of retrenching to its core products. It's expected to close around year's end.

- check out this release for more

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.